Home › Compare › BPSR vs GBDC

BPSR vs GBDC: Dividend Comparison 2026

BPSR yields 3333.33% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BPSR wins by $1244041712869.55M in total portfolio value
10 years
BPSR
BPSR
● Live price
3333.33%
Share price
$0.06
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1244041712890.40M
Annual income
$1,174,716,366,071,938,000.00
Full BPSR calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — BPSR vs GBDC

📍 BPSR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBPSRGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BPSR + GBDC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BPSR pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BPSR
Annual income on $10K today (after 15% tax)
$283,333.33/yr
After 10yr DRIP, annual income (after tax)
$998,508,911,161,147,300.00/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, BPSR beats the other by $998,508,911,147,164,200.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BPSR + GBDC for your $10,000?

BPSR: 50%GBDC: 50%
100% GBDC50/50100% BPSR
Portfolio after 10yr
$622020856455.62M
Annual income
$587,358,183,044,194,400.00/yr
Blended yield
94.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

BPSR
No analyst data
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BPSR buys
0
GBDC buys
0
No recent congressional trades found for BPSR or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBPSRGBDC
Forward yield3333.33% ✓11.86%
Annual dividend / share$2.00 ✓$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1% ✓
Portfolio after 10y$1244041712890.40M ✓$20.85M
Annual income after 10y$1,174,716,366,071,938,000.00 ✓$16,450,733.83
Total dividends collected$1239274250481.68M ✓$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: BPSR vs GBDC ($10,000, DRIP)

YearBPSR PortfolioBPSR Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$344,033$333,333.33$12,492$1,791.70+$331.5K → BPSR
2$11,085,665$10,717,549.33$16,527$3,160.58+$11.07M → BPSR
3$334,616,633$322,754,971.08$23,588$5,904.90+$334.59M → BPSR
4$9,462,934,690$9,104,894,892.71$37,141$11,901.65+$9462.90M → BPSR
5$250,766,259,005$240,640,918,887.41$66,205$26,463.38+$250766.19M → BPSR
6$6,228,082,462,189$5,959,762,565,053.11$137,452$66,612.65+$6228082.32M → BPSR
7$144,998,525,500,125$138,334,477,265,582.72$342,372$195,298.53+$144998525.16M → BPSR
8$3,165,074,899,913,431$3,009,926,477,628,297.00$1,053,292$686,954.33+$3165074898.86M → BPSR
9$64,790,043,755,570,470$61,403,413,612,663,110.00$4,111,439$2,984,416.95+$64790043751.46M → BPSR
10$1,244,041,712,890,398,500$1,174,716,366,071,938,000.00$20,849,974$16,450,733.83+$1244041712869.55M → BPSR

BPSR vs GBDC: Complete Analysis 2026

BPSR — Stock

Organicell Regenerative Medicine, Inc. processes, distributes, and supplies biologically processed cellular and tissue-based products in the United States. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. has an agreement with Regenerative Care Network to study potential therapeutic benefits of Zofin for patients with heart failure. Organicell Regenerative Medicine, Inc. was founded in 2011 and is headquartered in Miami, Florida.

Full BPSR Calculator →

GBDC — BDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this BPSR vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BPSR vs SCHDBPSR vs JEPIBPSR vs OBPSR vs KOBPSR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.